Advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation

Active Grant Awarded

Award ID
R01HL183395
Recipient
Awarding agency
Obligated
$876,614

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 5% complete
Place of performance
Chicago, IL 60611, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded Grant R01HL183395 to Ann & Robert H Lurie Children's Hospital of Chicago on August 27, 2026, obligating $876,614 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a multisite prospective cohort study of 400 children in English- and Spanish-language families who use long-term invasive home mechanical ventilation (LTMV), tracking acute respiratory infections (ARIs) for 12 months. The study tests whether modifiable factors in clinical decision making, including treatment selection and triage, are associated with ARI progression and emergency department or hospital use. The stated goal is treatment strategies that increase healthy days at home and quality of life for this population while reducing ED visits and hospitalizations.

Place of performance is Chicago, IL 60611, USA, and the award runs from August 27, 2026 through May 31, 2031. The assistance type is a grant.

Description

Abstract
Children who use invasive long-term (HOME) mechanical ventilation (LTMV) are a growing population of pediatric patients with the highest healthcare costs of all U.S. Children ($>2 billion/year). Acute respiratory infec- tion (ARIS) is their #1 cause of death and hospitalization (annual mortality of 5%). While prior research has identified predictors of ARI severity in healthy children, these studies do not apply to children with LTMV who already use oxygen and positive pressure ventilation. Our preliminary work has established that wide variation in care and outcomes in pediatric LTMV may be influenced by multiple factors, such as parental self-efficacy managing their children's complex HOME care regimens and vital sign monitoring. Prior influential research char- acterizing early respiratory illness symptomatology and management in other cardiorespiratory conditions has demonstrated that monitoring of physiologic changes at HOME coupled with care standardization greatly IM- proves child and family outcomes. However, there is no such comparable empirical evidence in children using LTMV to inform and optimize treatment strategies. Our central hypothesis is that there are modifiable factors impacting clinical decision making, including treatment selection and triage, that are associated with ARI progression and ED/hospital use in children with LTMV. Our core premise of this work is that identifying whether and how these modifiable factors are associated with ARI outcomes can lead to more effective clinical management tailored to this population's unique needs that will increase the healthy days at HOME and quality of life while reducing costs ED visits/hospitalizations. To test our hypothesis, we will conduct a multisite prospective cohort study of 400 children in english and span- ISH language families using LTMV for 12 months of ARIS from start of symptoms through each ARI peak and resolution. This epidemiologic data will allow US to test whether a robust set of modifiable multilevel factors are associated with ARI severity (aim 1). Using an embedded mixed-methods design, we will enrich our data further with 1) novel in-HOME physiologic data (e.g., end-tidal carbon dioxide, etc.) using wireless device to DE- termine whether patterns of physiologic changes can predict ARI progression (aim 2); and 2) qualitative data to contextualize the factors influencing at HOME treatment and triage decision-making and identify targets for early risk stratification tools and/or early clinical-decision support (aim 3). Overall, this work will be an essential step towards our long-term goal to develop evidence-based treatment models that reduce ARI-related morbid- ITY/mortality in children with LTMV. This work is significant in developing critically needed evidence-based strat- egies that provide effective and family-centered care for children with LTMV, a vulnerable pediatric population with high healthcare costs and caregiving stress.

Quick answers

Who received award R01HL183395?

R01HL183395 was awarded to ANN & Robert H Lurie Childrens Hospital Of Chicago by National Heart Lung and Blood Institute (National Institutes of Health) on August 27, 2026.

How much is award R01HL183395 worth?

$876,614 has been obligated on R01HL183395.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award